FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2278-2281 November 30, 2006 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Nitrogen-containing bisphosphonates are used widely for the management of metastatic cancer in bone (intravenous zoledronic acid or pamidronate), for the prevention and treatment of osteoporosis (oral alendronate, risedronate, and ibandronate and intravenous ibandronate), for the treatment of Paget's disease of bone (intravenous pamidronate and oral alendronate and risedronate), and for the short-term management of acute hypercalcemia (intravenous zoledronic acid and pamidronate). The nitrogen moiety attached to the side chain of the middle carbon of the phosphorus–carbon–phosphorus bisphosphonate backbone renders these drugs much more potent as inhibitors of bone resorption than the bisphosphonates that do not contain nitrogen (etidronate and clodronate). . . . [Full Text of this Article]

Source Information

Dr. Bilezikian is a professor of medicine and pharmacology at the College of Physicians and Surgeons, Columbia University, New York.

This article has been cited by other articles:

• Mazziotti, G., Giustina, A., Canalis, E., Bilezikian, J. P. (2009). Treatment of glucocorticoid-induced osteoporosis. Therapeutic Advances in Musculoskeletal Diseases 1: 27-34 [Abstract]  
• Hegge, K. A., Fornoff, A. S., Gutierres, S. L., Haack, S. L. (2009). New Therapies for Osteoporosis. Journal of Pharmacy Practice 22: 53-64 [Abstract]  
• Sedghizadeh, P. P., Stanley, K., Caligiuri, M., Hofkes, S., Lowry, B., Shuler, C. F. (2009). Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: An institutional inquiry. Journal of the American Dental Association 140: 61-66 [Abstract] [Full Text]  
• Pazianas, M., Russell, R. G. G., Fogelman, I. (2009). Osteonecrosis of the Jaw: More Heat Than Light. JNM 50: 6-7 [Full Text]  
• Edwards, B. J., Hellstein, J. W., Jacobsen, P. L., Kaltman, S., Mariotti, A., Migliorati, C. A., for the American Dental Association Council on Sci, (2008). Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: An advisory statement from the American Dental Association Council on Scientific Affairs. Journal of the American Dental Association 139: 1674-1677 [Abstract] [Full Text]  
• Shaw, N. J (2008). Management of osteoporosis in children. Eur J Endocrinol 159: S33-S39 [Abstract] [Full Text]  
• Drake, M. T., Clarke, B. L., Khosla, S. (2008). Bisphosphonates: Mechanism of Action and Role in Clinical Practice. Mayo Clin Proc. 83: 1032-1045 [Abstract] [Full Text]  
• Qiang, Y.-W., Shaughnessy, J. D. Jr, Yaccoby, S. (2008). Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood 112: 374-382 [Abstract] [Full Text]  
• Raje, N., Woo, S.-B., Hande, K., Yap, J. T., Richardson, P. G., Vallet, S., Treister, N., Hideshima, T., Sheehy, N., Chhetri, S., Connell, B., Xie, W., Tai, Y.-T., Szot-Barnes, A., Tian, M., Schlossman, R. L., Weller, E., Munshi, N. C., Van Den Abbeele, A. D., Anderson, K. C. (2008). Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw. Clin. Cancer Res. 14: 2387-2395 [Abstract] [Full Text]  
• (2008). Should We Be Concerned About Jaw Osteonecrosis with Oral Bisphosphonates?. JWatch General 2008: 1-1 [Full Text]  
• Ebeling, P. R. (2008). Osteoporosis in Men. NEJM 358: 1474-1482 [Full Text]  
• Dodson, T. B., Raje, N. S., Caruso, P. A., Rosenberg, A. E. (2008). Case 9-2008 -- A 65-Year-Old Woman with a Nonhealing Ulcer of the Jaw. NEJM 358: 1283-1291 [Full Text]  
• Aapro, M., Abrahamsson, P. A., Body, J. J., Coleman, R. E., Colomer, R., Costa, L., Crino, L., Dirix, L., Gnant, M., Gralow, J., Hadji, P., Hortobagyi, G. N., Jonat, W., Lipton, A., Monnier, A., Paterson, A. H. G., Rizzoli, R., Saad, F., Thurlimann, B. (2008). Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19: 420-432 [Abstract] [Full Text]  
• Cartsos, V. M., Zhu, S., Zavras, A. I. (2008). Bisphosphonate Use and the Risk of Adverse Jaw Outcomes: A medical claims study of 714,217 people. Journal of the American Dental Association 139: 23-30 [Abstract] [Full Text]  
• Shaw, N J (2007). Osteoporosis in paediatrics. EDUCATION AND PRACTICE 92: 169-175 [Full Text]  
• Ruggiero, S.L., Drew, S.J. (2007). Osteonecrosis of the Jaws and Bisphosphonate Therapy. JDR 86: 1013-1021 [Abstract] [Full Text]  
• Brown, J. E., Ellis, S. P., Lester, J. E., Gutcher, S., Khanna, T., Purohit, O.-P., McCloskey, E., Coleman, R. E. (2007). Prolonged Efficacy of a Single Dose of the Bisphosphonate Zoledronic Acid. Clin. Cancer Res. 13: 5406-5410 [Abstract] [Full Text]  
• Shenker, N. G., Jawad, A. S. M. (2007). Bisphosphonates and osteonecrosis of the jaw. Rheumatology (Oxford) 46: 1049-1051 [Full Text]  
• Shoback, D. (2007). Update in Osteoporosis and Metabolic Bone Disorders. J. Clin. Endocrinol. Metab. 92: 747-753 [Abstract] [Full Text]